Marker Therapeutics, Inc.

MRKR

US57055L2060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
4.97 ^USD	-4.24%		-8.47%	-9.64%

01/07	Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Index	CI
01/07	Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Index	CI

Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Index

July 01, 2024

Latest news about Marker Therapeutics, Inc.

Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Index	01/07	CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Index	01/07	CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Growth Index	01/07	CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Growth Index	01/07	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	16/05	MT
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	30/04	MT
North American Morning Briefing : Stocks Edge -2-	27/03	DJ
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
North American Morning Briefing : Markets on Hold -2-	20/03	DJ
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	22/01	CI
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08/01	CI
Top Midday Gainers	12/12	MT
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	11/12	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	10/11	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	11/23/11	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q2 Revenue $762,658	15/23/15	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Transcript : Marker Therapeutics, Inc. - Special Call	09/23/09
Marker Therapeutics Says Non-clinical Data Show MT-401 Inducing Anti-tumor Activity in Specific Setting	07/23/07	MT
Marker Therapeutics Says Acute Myeloid Leukemia Treatment Candidate Granted Orphan Drug Designation in European Union	10/23/10	MT
Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen-Specific T Cell Product Candidate, Mt-401	10/23/10	CI
Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer	04/23/04	CI
Correction: Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia	27/23/27	MT

Chart Marker Therapeutics, Inc.

Duration

Period

More charts

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.97 USD

Average target price

11 USD

Spread / Average Target

+121.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MARKER THERAPEUTICS, INC.	-9.64%	44.33M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research